Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...

Books with integrated notes and video explainers now available for aspiring solicitors London, United Kingdom – ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...

Leaders of an effort to finance a $16.7 million renovation of Joplin’s Memorial Hall told residents during a Monday night presentation that they were hoping to receive approval of a memorandum of ...

Complement activation in patients with AAV who are in remission may be reflective of ongoing renal scarring. Persistent complement activation during disease remission in antineutrophil cytoplasmic ...

AIs can outperform humans easily on short tasks, but longer ones are the true hurdle to overcome before we can deem them to be truly intelligent systems. When you purchase through links on our site, ...

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG. The indicated, FDA-approved use for eculizumab (Soliris; Alexion and ...

Recent literature suggests that innate immune system effectors may drive poor patient outcomes in acute ischemic stroke (AIS) through complications such as hemorrhagic transformation. Biomarkers for ...